A Cost-Effectiveness Analysis of Radiofrequency Renal Denervation for Uncontrolled Hypertension Based on the SPYRAL HTN-ON Med Trial in the Netherlands

Author(s)

Pietzsch JB1, Cao K1, Ryschon A1, van Kuijck J2, Spiering W3, Daemen J4
1Wing Tech Inc., Menlo Park, CA, USA, 2Medtronic Trading NL B.V., Eindhoven, North Brabant, Netherlands, 3Utrecht University, Utrecht, Utrecht, Netherlands, 4Erasmus Medical Center, Rotterdam, South Holland, Netherlands

OBJECTIVES: Radiofrequency renal denervation (RF RDN) is increasingly recognized as an adjunct therapy option for uncontrolled hypertension, including resistant hypertension. This study sought to assess the cost-effectiveness of RF RDN in the Dutch healthcare setting.

METHODS: Clinical events, quality-adjusted survival, and costs at a ten-year and lifetime horizon were projected with a previously published and validated Markov model based on multivariate risk equations, including the Framingham equations. Risk reductions from changes in office-based systolic blood pressure (oSBP) were based on a meta-regression of 47 hypertension randomized-controlled trials (RCTs). The base case -4.9 mmHg oSBP reduction in the treatment group obtained from the SPYRAL HTN-ON MED full cohort study, in which both groups maintained use of antihypertensive medication. The relative risks (RR) of clinical events at ten years were projected for stroke, myocardial infarction (MI), angina pectoris/coronary heart disease (AP/CHD), heart failure (HF), end-stage renal disease (ESRD), cardiovascular death (CVD) and all-cause death (ACD). The lifetime incremental cost-effectiveness ratio (ICER) was examined against a Dutch burden of disease-derived willingness-to-pay threshold of €20,000 per quality-adjusted life-year (QALY) gained, with costs and effects discounted 3.0% and 1.5%, respectively, per Dutch guidelines.

RESULTS: RF RDN led to a RR and absolute risk reduction (ARR) in clinical events (0.80 and 1.7% for stroke, 0.88 and 0.9% for MI, 0.89 and 1.6% for AP/CHD, 0.72 and 1.4% for HF, 0.96 and 0.014% for ESRD, 0.86 and 1.0% for CVD, and 0.93 and 0.9% for ACS, respectively). Over a lifetime horizon, the therapy added 0.61 QALYs with an incremental cost of €3,828, yielding an ICER of €6,277 per QALY gained, below the willingness-to-pay threshold of €20,000 per QALY gained.

CONCLUSIONS: Findings from this analysis suggest RF RDN adds meaningful clinical benefit at incremental cost that render it a cost-effective intervention in the Dutch healthcare system.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

EE694

Topic

Clinical Outcomes, Economic Evaluation, Study Approaches

Topic Subcategory

Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Decision Modeling & Simulation

Disease

Cardiovascular Disorders (including MI, Stroke, Circulatory), Medical Devices

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×